Overview: Executive Officer Communications

The Ontario Public Drug Programs is committed to following the principles of good drug system governance that are enshrined in the legislation by:

  • striving to meet the needs of Ontarians, as patients, consumers and taxpayers
  • involving consumers and patients in a meaningful way
  • operating transparently, to the extent possible, for all persons with an interest in the system, including, without being limited to, patients, health care practitioners, consumers, manufacturers, wholesalers and pharmacies
  • aiming to consistently achieve value-for-money and ensure the best use of resources at every level of the system
  • making funding decisions for drugs on the best clinical and economic evidence available, communicating those decisions openly, in as timely a manner as possible

Find the most recent communications below.

Executive Officer Communications

2024
DateTitle

February 9

Executive Officer Notice: Publicly Funded COVID-19 PCR Testing Services in Ontario Pharmacies 

February 9Notice: Proposed Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Change Mark-ups Paid to Dispensers
February 9

Update: Executive Officer Notice: Clarification on Ontario Naloxone Program for Pharmacies

January 26

Executive Officer Notice: Update to Ozempic Listing – Change in Status to Limited Use Benefit (Effective date: January 31, 2024)

January 8Executive Officer Notice: Clarification on Restrictions to the Extemporaneous Preparations Policy

January 3

Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies
(Effective date: January 3, 2024)

2023
DateTitle
December 27

Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #10

December 22

Executive Officer Notice: Administration of COVID-19 Vaccines in Ontario Pharmacies.

December 15

Executive Officer Notice: Update to Biosimilar Policy (Effective date: Dec. 11, 2023)

December 14Executive Officer Notice: Elimination of Facilitated Access to HIV/AIDS Drug Products from the Ontario Drug Benefit Formulary/CDI

December 12

 

Executive Officer Notice: Prescribing and Dispensing Oral Antiviral Treatments for Respiratory Viruses in Ontario Pharmacies

November 30Executive Officer Notice : Implementation of Renewed Three-Year Generics Initiative Between the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association
November 22

Update: Executive Officer Notice: Update to Biosimilar Policy
(Effective date: Nov. 9, 2023)

November 17

 

Executive Officer Notice: Dispensing Publicly Funded Remdesivir (Veklury™) in Ontario Pharmacies

October 19Proposed regulatory amendments under the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act to modernize submission requirements for
“well-established drugs.”

October 13

 

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Update: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies

October 10

Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #9

October 10Executive Officer Notice: Ontario Drug Benefit Program – New Online Applications and Forms
September 26

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Update: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccines in Ontario Pharmacies

 

September 25

* Please refer to entry posted on January 3, 2024 for the latest updated EO Notice.

Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies (Effective date: October 1, 2023)

September 21Executive Officer Notice: Removal of temporary PINs for Humalog® (insulin lispro): Shortage of the insulin lispro biosimilar (Admelog®) is resolved
September 15

Executive Officer Notice: Administration of Publicly Funded Influenza Vaccine in Ontario Pharmacies

September 11Executive Officer Notice: Changes to the Dispensing of Publicly Funded Approved Non-Prescription Drugs for Long-Term Care Home Residents

 

July 31

Executive Officer Notice: Dispensing Publicly Funded ranibizumab in Ontario Pharmacies
(Effective date: July 31, 2023)

 

July 26

* Please refer to entry posted on January 3, 2024 for the latest updated EO Notice.

Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies
(Effective date: July 29, 2023)

July 7

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Update: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Updated July 21, 2023)

July 6

Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #8

 

April 30

* Please refer to entry posted on January 3, 2024 for the latest updated EO Notice.

Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies
(Effective date: April 30, 2023)

April 24

* Please refer to entry posted on November 17, 2023 for the latest updated EO Notice.

Executive Officer Notice: Dispensing Publicly Funded Remdesivir (VekluryTM) in Ontario Pharmacies 
(Effective date: April 24, 2023)

 

April 21

*Please refer to entry posted on December 12, 2023 for the latest updated EO Notice and FAQs.

Executive Officer Notice: Prescribing & Dispensing Publicly Funded Paxlovid in Ontario Pharmacies
(No changes from December 12)

 

April 13

Executive Officer Notice: Temporary PINs for Humalog® (insulin lispro): Shortage of the insulin lispro biosimilar (Admelog®)
(Effective date: March 31, 2023)

 

April 6

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies

 

April 3

Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Extend the Reconciliation Adjustment to Pharmacy Payments
(Effective date: April 1, 2023)

 

March 31

Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020
(Effective date: April 1, 2023)

 

March 13

Executive Officer Notice: Biosimilar Policy 
(Effective date: March 10, 2023)

 

March 6

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date March 6, 2023)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date March 6, 2023)

 

February 28

Notice: Proposed Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Extend Reconciliation Adjustment to Pharmacy Payments

 

February 6

*Please refer to entry posted on December 12, 2023 for the latest updated EO Notice and FAQs.

Executive Officer Notice: Prescribing & Dispensing Publicly Funded Paxlovid in Ontario Pharmacies
(No changes from December 12)

 

January 25

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies

 

January 19

Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #7

2022
DateTitle

 

December 22

* Please refer to entry posted on January 3, 2024 for the latest updated EO Notice.

Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies 
(Effective date: January 1, 2023)

 

December 21

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date December 21, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date December 21, 2022)

 

December 15

Executive Officer Notice: Administration of Publicly Funded Influenza Vaccine in Ontario Pharmacies
(No change from September 20, 2022)

 

December 12

Updated: Executive Officer Notice: Supplying of Publicly Funded Evusheld™ for Pre-Exposure Prophylaxis of COVID‑19 in Ontario Pharmacies
(Effective date December 12, 2022)

 

December 12

*Please refer to entry posted on December 12, 2023 for the latest updated EO Notice and FAQs.

Executive Officer Notice: Prescribing & Dispensing Publicly Funded Paxlovid™ in Ontario Pharmacies
(Effective date December 12, 2022)

 

December 12

Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies (ONPP)
November 22

Executive Officer Notice: Replacement of one Mail Direct Email Service with Microsoft Office 365 Email Account

 

November 8

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date November 8, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date November 8, 2022)

 

October 17

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date October 17, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing 
(Effective date October 17, 2022)

 

October 6

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies

 

October 3

*Please refer to entry posted on December 12, 2022 for the updated EO Notice and Qs & As.

Notice from the Executive Officer: Supplying of Publicly Funded Evusheld™ for Pre-Exposure Prophylaxis of COVID‑19 in Ontario Pharmacies

 

September 26

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date September 26, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date September 26, 2022)

 

September 20

*Please refer to entry posted on December 15, 2022 for the updated EO Notice and Qs & As.

Notice from the Executive Officer: Pharmacy administration of publicly funded influenza vaccines and claims submission using the Health Network System, 2022–2023

 

September 12

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date September 12, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date September 12, 2022)

 

September 1

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date September 1, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date September 1, 2022)

August 22

Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #6

 

August 9

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies

 

August 8

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date August 8, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date August 8, 2022)

 

July 28

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date July 28, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date July 28, 2022)

July 28

Executive Officer Notice: Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program

July 26

* Please refer to entry posted on February 6, 2023 for the latest EO Notice and FAQs.

Executive Officer Notice: Supplying of Publicly Funded Oral Antiviral COVID‑19 Treatment in Ontario Pharmacies (Effective date: April 12, 2022, Updated July 26, 2022)

 

July 14

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date July 14, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date July 14, 2022)

June 24Notice from the Executive Officer: Temporary Benefit Nutrition Products: Shortage of infant formulas for infants with food allergies and certain medical conditions
May 31Update to the Executive Officer Notice of interim change to Extemporaneous Preparations Policy for Anti-infectives
May 13Notice from the Executive Officer:
Pan-Canadian Select Molecules Price Initiative for Generic Drugs

 

May 2

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date May 2, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date May 2, 2022)

May 1Executive Officer Notice: Update to Home Care Eligibility under the Ontario Drug Benefit Program

 

April 25

* Please refer to entry posted on February 6, 2023 for the latest EO Notice and FAQs.

Executive Officer Notice: Supplying of Publicly Funded Oral Antiviral COVID‑19 Treatment in Ontario Pharmacies
(Effective date: April 12, 2022, Updated April 25, 2022)

April 12

* Please refer to entry posted on February 6, 2023 for the latest EO Notice and FAQs.

Executive Officer Notice: Supplying of Publicly Funded Oral Antiviral COVID‑19 Treatment in Ontario Pharmacies
(Effective date: April 12, 2022)

 

April 12

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies –Eligibility

April 8Executive Officer Notice: Providing Support for Persons with an Emergency Authorization for Humanitarian Reasons under Ontario Public Drug Programs
(Effective Date: April 6, 2022)

 

April 7

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date April 7, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date April 7, 2022)

 

April 1

Updated — Notice from the Executive Officer: Reimbursement and Claims Submission using the Health Network System relating to Drugs for Medical Assistance in Dying

 

March 25

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date March 25, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date March 25, 2022)

 

March 21

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies

March 17Executive Officer Notice: Reconciliation Adjustment Percentages for 2022/23 to Improve the Value of Pharmacy Payments
March 15

Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #5

March 7Executive Officer Notice: Health Network System Changes to Reimbursement of Blood Glucose Test Strips
February 22

Notice from the Executive Officer: Funding of Insulin Aspart and Insulin Glargine under the Ontario Drug Benefit Program

 

February 18

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date February 18, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date February 18, 2022)

February 18

Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020

February 4

 

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies — Eligibility

January 17

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Updated Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies

 

January 13

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date January 13, 2022)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date January 13, 2022)

January 11Executive Officer Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation
2021
DateTitle
December 31

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies — Eligibility

 

December 20

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date December 20, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date December 20, 2021)

 

December 17

* Please refer to entry posted on October 13, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date December 17, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date December 17, 2021)

 

December 7

Update: Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System, 2021–2022

 

December 2

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated:Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date December 2, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date December 2, 2021)

December 1

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies — Eligibility

November 27

* Please refer to entry posted on February 9, 2024 for the latest updated EO Notice.

Updated: Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies — Eligibility

 

November 25

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date November 25, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date November 25, 2021)

 

November 18

* Please refer to entry posted on March 21, 2022 for the latest updated EO Notice on Eligibility

Updated Notice from the Executive Officer: Publicly Funded COVID‑19 Testing Services in Ontario Pharmacies: Eligibility Criteria

November 17

*Please refer to entry posted on December 7, 2021 for the latest updated EO Notice

Update to Executive Officer Notice: Administration of the Publicly Funded Influenza Vaccines in Ontario Pharmacies — Pharmacy Technicians

 

November 3

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date November 3, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date November 3, 2021)

October 27

Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #4

 

October 8

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date October 8, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date October 8, 2021)

October 8

*Please refer to entry posted on December 7, 2021 for the latest updated EO Notice

Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System, 2021–2022

 

October 1

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date October 1, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date October 1, 2021)

September 22

Updated Executive Officer Notice: Publicly Funded COVID‑19 Antigen Point-of-Care Testing in Ontario Pharmacies

 

September 21

Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020
(Effective date September 27, 2021)

September 8

Executive Officer Notice: Publicly Funded COVID‑19 Antigen Point-of-Care Testing in Ontario Pharmacies

 

September 8

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date September 8, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date September 8, 2021)

 

September 1

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date September 1, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date September 1, 2021)

 

August 27

* Please refer to entry posted on November 18 2021 for the latest updated EO Notice on Eligibility

Updated Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria

 

August 18

* Please refer to entry posted on October 13, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date August 18, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing
(Effective date August 18, 2021)

 

July 5

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date July 5, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing
(Effective date July 5, 2021)

 

June 25

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 25, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing
(Effective date June 25, 2021)

 

June 17

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 17, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing

 

June 14

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 14, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing
(Effective date June 14, 2021)

June 14

Executive Officer Notice: Improved Access to Exceptional Access Program Drugs for Ontarians Living Near Manitoba and Quebec Borders under the Ontario Drug Benefit Program

 

June 4

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 4, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing
(Effective date June 4, 2021)

June 4

Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #3

 

May 31

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 31, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 31, 2021)

 

May 31

* Please refer to entry posted on August 27 2021 for the latest updated EO Notice on Eligibility

Updated Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria

 

May 23

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 23, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date May 13, 2021) (FYI: No change from May 13 posting)

May 21

Executive Officer Notice: Administration of Second Doses for Individuals who received First Dose of AstraZeneca / Covishield COVID‑19 Vaccines in Ontario Pharmacies

 

May 18

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date May 13, 2021) (FYI: No change from May 13 posting)

 

May 13

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date May 13, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date May 13, 2021)

May 11

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Executive Officer Notice: Pause of the Administration of First Doses of Publicly Funded AstraZeneca / Covishield COVID‑19 Vaccines in Ontario Pharmacies

May 11

Executive Officer Notice: Updated Income Eligibility Thresholds for the Seniors Co-Payment Program under the Ontario Drug Benefit Program

 

May 6

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date May 6, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing

May 5

Notice from the Executive Officer: Funding of enoxaparin under the Ontario Drug Benefit Program

 

April 30

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date April 30, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date April 30, 2021)

 

April 23

* Please refer to entry posted on May 31 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers

Updated Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria

 

April 19

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date April 19, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date April 19, 2021)

April 16Executive Officer Notice of interim change to Extemporaneous Preparations Policy for Anti-infectives for Post-Hospital Use
April 15Executive Officer Notice: Proposed Legislative and Regulatory Amendments — Dissolution of the Citizens’ Council and the Pharmacy Council under the Ontario Drug Benefit Act

 

April 7

* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers

Updated: Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria

 

April 1

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date April 1, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date April 1, 2021)

March 26Executive Officer Notice: Proposal to update the Income Eligibility Thresholds for the Seniors Co-Payment Program under the Ontario Drug Benefit Program
March 25

Notice from the Executive Officer: Funding of Adalimumab under the Ontario Drug Benefit Program

March 22

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Eligibility
(Effective date March 22, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies — Billing
(Effective date March 22, 2021)

March 18

Notice from the Executive Officer: The Ontario Drug Programs Reference Manual, Revision #2

Notice from the Executive Officer: Regulatory Amendments relating to Recordkeeping Requirements for Pharmacies and Dispensing Physicians under the Ontario Drug Benefit Program

March 16Executive Officer Notice: Update of the OPDP At A Glance Report
March 10

* Please refer to entry posted on December 22, 2023 for the latest updated EO Notice.

Executive Officer Notice: Administration of Publicly Funded COVID‑19 Vaccine in Ontario Pharmacies
(Effective date March 10, 2021)

 

March 5

* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers

Updated: Executive Officer Notice: Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria

March 5Notice from the Executive Officer: Reconciliation Adjustment Percentages for 2021/22 to Improve the Value of Pharmacy Payments

February 19

 

* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers

Executive Officer Notice: Expansion of Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies (Eligibility and Investigation Numbers)
(Effective February 19, 2021)

Updated Executive Officer Notice: Expansion of Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies (Billing, Pharmacy Record Documentation)
(Effective February 19, 2021)

January 25

Notice from the Executive Officer: Funding of Insulin Lispro under the Ontario Drug Benefit Program

January 15

Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020

2020
DateTitle
December 18Executive Officer Notice: Administering the Flu Vaccine to Children Age 2 and older under the Universal Influenza Immunization Program 2020/21
December 18

Executive Officer Notice: Funding of Avsola (Infliximab) under the Ontario Drug Benefit Program

December 14

Executive Officer Notice: Update to Drug Benefit Claim — Submission/Reversal Forms

December 14Executive Officer Notice: Update to Special Authorization — Allergen (SAA) Form
December 8

* Please refer to entry posted on April 23 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
** Please refer to entry posted on February 19, 2021 for the latest updated EO Notice on Billing and Pharmacy / Patient Qs and As

Executive Officer Notice: Update — Expansion of Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies
(Effective December 11, 2020)

December 7Executive Officer Notice: Fluarix influenza vaccine injection added to the Universal Influenza Immunization Program 2020/21 for Pharmacists Administering Flu Vaccines
November 30Executive Officer Notice: FluMist Nasal Spray added to the Universal Influenza Immunization Program 2020/21 for Pharmacists Administering Flu Vaccines
November 20

Executive Officer Notice: Forgery Notification Alerts in the Health Network System (HNS), including the Narcotics Monitoring System (NMS)

November 5

* Please refer to entry posted on April 23 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
** Please refer to entry posted on February 19, 2021 for the latest updated EO Notice on Billing and Pharmacy / Patient Qs and As

Notice from the Executive Officer: Expansion of Specimen Collection for COVID‑19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies

October 26Notice from the Executive Officer: Updates to Pharmacists Administering Flu Vaccine to patients without a Health card number
October 26Notice from the Executive Officer: Reminder to pharmacies on extensions to expiry dates on Ontario health card numbers
October 22Notice from the Executive Officer: Proposal to Streamline Recordkeeping Requirements for Pharmacies and Dispensing Physicians under the Ontario Drug Benefit Program
October 21Executive Officer Notice: Funding of Emerade™ (Epinephrine Auto-Injector) through the Allergen Program
October 6Executive Officer Notice: Proposal to Improve Access to Exceptional Access Program Drugs for Ontarians Living Near Manitoba and Quebec Borders
October 2

Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System

August 24

Executive Officer Notice: Funding of Riximyo (rituximab) and Ruxience (rituximab) under the Ontario Drug Benefit Program

August 5Executive Officer Notice: Funding of Allerject® (Epinephrine Auto-Injector) through the Allergen Program
July 30Executive Officer Notice: Inspections Return to Work
June 12

Executive Officer Notice: Removal of the 30-days’ Supply Dispensing Limit Recommendation

May 21Notice from the Executive Officer: Funding of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler as a Temporary Benefit on the Ontario Drug Benefit (ODB) Formulary
May 13

Notice from the Executive Officer: Regulatory Amendments to Ontario Drug Benefit Program Co-payments

May 13

Notice from the Executive Officer: Changes to the Trillium Drug Program in Response to COVID‑19

May 1Notice from the Executive Officer: Proposed Regulatory Amendments to Ontario Drug Benefit (ODB) Program Co-payments and Dispensing Fees
April 23Notice from the Executive Officer: Brand Reference Price Regulations Amendment
April 23Notice from the Executive Officer: Drug Submissions for Ontario Drug Benefit (ODB) Program during the COVID‑19 Public Health Emergency

 

April 15

* Please also refer to entry December 12 under 2022 for latest information on the Ontario Naloxone Program for Pharmacies (ONPP) in regards to the Quarterly Report Back Form.

Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies (ONPP)

April 15Notice: Ontario Drug Benefit Program and Exceptional Access Program Changes during the COVID‑19 Public Health Emergency
April 7Notice from the Executive Officer: Regulation Amendments to Private Label Products and Brand Reference Pricing Rules
April 1

Notice: Extending Submission Period for Electronic Drug Claim Reversals and The Ontario Drug Programs Reference Manual, Revision #1

April 1

Notice: Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program

March 30Notice from the Executive Officer: Proposed amendments to the effective date of changes to allow Private Label Products to be funded under the Ontario Drug Benefit (ODB) Program and Designated as Interchangeable Products on the ODB Formulary
March 30Notice from the Executive Officer: Proposed Regulatory Amendments on Rules for Determining Brand Reference Prices
March 30

Notice from the Executive Officer: Funding of Truxima (rituximab) under the Ontario Drug Benefit Program

March 23Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation
March 20Notice: Ontario Drug Benefit (ODB) Program Changes and Guidance for Dispensers during the COVID‑19 Public Health Emergency
March 2Notice: Reconciliation Adjustment Percentages for 2020/21 to Improve the Value of Pharmacy Payments
2019
DateTitle
December 23Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to reduce Administrative Burden to Drug Manufacturers and Pharmacies
December 23Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation Notice
December 16Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 made under the Drug Interchangeability and Dispensing Fee Act to reduce restrictions on Private Label Products and Ordinary Commercial Term benefits
December 16

Notice: Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020

* Please refer to entry posted on September 21, 2021 for an amendment to the Policy effective September 27, 2021

December 16

Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Improve the Value of Pharmacy Payments

October 28Notice: Proposal to Improve the Value of Pharmacy Payments
October 28Notice from the Executive Officer: Proposal to Reduce Administrative Burden to Drug Manufacturers and Pharmacies
October 18

Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System

October 1Notice from the Executive Officer: Updates to the Drug Evaluation Process for Biosimilar Products
September 12Notice from the Executive Officer: Funding Flash Glucose Monitoring System Through the Ontario Drug Benefit Program
July 31

Notice from the Executive Officer: Updated Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program

July 24Notice from the Executive Officer Submission Requirements: Flash GlucoseMonitoring (FGM)
July 4Notice from the Executive Officer: Updates to the Ontario Guidelines for Drug Submission and Evaluation
June 4Notice from the Executive Officer: Change to the Health Network System Subscription Agreement for Pharmacy Operators
April 26Notice from the Executive Officer: Proposals to Establish More Efficient Pharmacy Reimbursement Policies
March 13Notice from the Executive Officer: Buprenorphine/Naloxone (Suboxone® and generics) Reimbursement Reminder under the Ontario Drug Benefit Program
February 27

Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+)

February 13Notice from the Executive Officer: Extension of the Temporary Facilitated Access Mechanism (Rheumatology) until March 31, 2019)
February 1

Notice from the Executive Officer: Administrative Monetary Penalty Issued for Acceptance of Rebates

January 2Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+)
2018
DateTitle
December 31Notice from the Executive Officer: Interim Extension of the Temporary Facilitated Access Mechanism (Rheumatology)
December 4Notice from the Executive Officer: Completion of Strengthening Pharmacy Payment Management
October 29Notice from the Executive Officer: Proposed Amendments to Regulations under the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act relating to Private Label Products
October 4

Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System

September 25Notice from the Executive Officer: Update on Claims Submission for Valved Holding Chambers through the Ontario Drug Benefit Program
September 20

Notice from the Executive Officer: Funding of Renflexis (infliximab) under the Ontario Drug Benefit Program

September 20

Notice from the Executive Officer: Funding of Glatect (glatiramer acetate) under the Ontario Drug Benefit Program

September 10
(Updated October 11)
Notice from the Executive Officer: Availability and Funding of AUVI-Q® (Epinephrine Auto-Injectors) as a Result of the Shortage of EpiPen® Products
August 14Notice from the Executive Officer: Claim Submission/Reversal and Special Authorization (Allergen) forms
July 30Notice from the Executive Officer: Update on OHIP+
May 4Notice from the Executive Officer: Refreshed ODB Report Card
May 1Notice from the Executive Officer: Update Regarding Strengthening Pharmacy Payment Management
March 29
(Updated
October 12)

Notice from the Executive Officer: Changes in the Way Pharmacies Verify Eligibility for Individuals Receiving Social Assistance

 

March 21
(Updated April 27)

* Please also refer to entry December 12, 2022 for new information on the Ontario Naloxone Program for Pharmacies (ONPP) in regards to the Quarterly Report Back Form.

Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP and Updates to the Existing Program

March 8

Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP

March 5Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs
March 2

Notice from the Executive Officer: Ontario Drug Benefit Act Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP)

February 21

Notice from the Executive Officer: Funding of Hepatitis B Drugs under the Ontario Drug Benefit Program

February 8Notice from the Executive Officer: Addition of Nurse Practitioners to the Palliative Care Facilitated Access (PCFA) Mechanism
January 24Notice from the Executive Officer: Edition 43 of the Ontario Drug Benefit Formulary
January 16Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendments to Align Maximum Days’ Supply of Prescriptions Dispensed for Ontario Works Recipients 25 years of Age and Older
January 10

Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP)

2017
DateTitle
December 22Notice from the Executive Officer: Drug Submission — Submission Requirements: Valved Holding Chambers (VHCs)
December 21Notice from the Executive Officer: Funding Valved-Holding Chambers through the Ontario Drug Benefit Program
December 14

Notice from the Executive Officer: Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program

December 14Notice from the Executive Officer: Temporary Facilitated Access Mechanism (Rheumatology) for Ontario Drug Benefit Recipients aged 24 years and under
December 1Notice from the Executive Officer: Removal of the Special Authorization (Allergen) Form for Pharmacy Dispensing of Epinephrine Auto-Injectors for Ontario Drug Benefit recipients
November 17Addendum: Notice from the Executive Officer: Addition of Agriflu® to the Universal Influenza Immunization Program
October 13

Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System for the 2017/2018 Influenza Immunization Season

September 21

Notice from the Executive Officer: Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for the Fentanyl Transdermal Patch

September 21Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Support the Homes for Special Care Modernization Initiative
September 1Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management
September 1Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare
August 23Notice from the Executive Officer: Notice from the Executive Officer: Thyroid (Desiccated Thyroid) Delisting
August 3

Notice from the Executive Officer: Funding of Mifepristone/Misoprostol (Mifegymiso)
(updated December 7, 2017)

August 1

Notice from the Executive Officer: Funding of filgrastim under the Ontario Drug Benefit Program

July 21

Notice from the Executive Officer: Funding of Brenzys (etanercept) under the Ontario Drug Benefit Program

July 11Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program
July 7

Notice from the Executive Officer: Ontario Drug Benefit Act, Legislative amendments to recognize the role of Nurse Practitioners in requesting Exceptional Access Program products and prescribing Listed Substances (Bill 87)

June 29Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management
March 16Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs
February 21

Notice from the Executive Officer: Funding of Hepatitis C drug products under the Ontario Drug Benefit Program

January 27Notice from the Executive Officer: Updated Reminder Regarding Delisting of High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program
2016
DateTitle
December 21

Notice from the Executive Officer: Funding of Grastofil (filgrastim) under the Ontario Drug Benefit program

December 1

Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program

November 30Notice from the Executive Officer: Update Regarding Palliative Care Access to High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program
October 24

Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines for 2016–2017 Season and Claims Submission using the Health Network System

October 07

Notice from the Executive Officer: Application of Generic Substitution to the Exceptional Access Program

September 26Notice from the Executive Officer: Regulation amendments to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products
September 16

Notice from the Executive Officer: Regulation to support the Safeguarding our Communities Act, 2015 (Patch for Patch Return Program)

September 16Notice from the Executive Officer: Drug Submission — Ontario Guidelines for Drug Submission and Evaluation 2016
September 02

Notice from the Executive Officer: Changes in the Way Social Assistance Clients Access Drug Coverage

For Social Assistance Clients

August 17 (Updated April 27)

* Please refer to entry December 12, 2022 for current information on the Ontario Naloxone Program for Pharmacies (ONPP). The materials below are available below for reference purposes.
* Please also refer to entry April 15 under 2020 for new information in regards to the Quarterly Report Back Form.

Notice from the Executive Officer: Reminder — Ontario Naloxone Program for Pharmacies (ONPP)
Notice from the Executive Officer: Ontario Naloxone Program for Pharmacies (ONPP)

August 15

* Please also refer to entry April 1 under 2022 for new information on the Medical Assistance in Dying Program. The materials below are available below for reference purposes.

Notice from the Executive Officer: Reimbursement and Claims Submissions using the Health Network System relating to Drugs for Medical Assistance in Dying

July 20

Notice from the Executive Officer: Changes to the Ontario Drug Benefit (ODB) Program Funding of Opioid Medications

July 4Notice from the Executive Officer: MedsCheck Program Enhancements
June 10

Notice from the Executive Officer: Health Network System (HNS) Changes to Support the Maximizing Quantity Dispensed for Chronic-Use Medications Initiative

June 1Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products
June 1Notice from the Executive Officer: Proposed Regulation under the Safeguarding our Communities Act (Patch for Patch Return Policy)
April 15Notice from the Executive Officer: Regulation Amendments to Expand Access to the Seniors’ Co-Payment Program under the Ontario Drug Benefit (ODB) Program
March 22Executive Officer Notice Drug Submission — Information Bulletin
March 15Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs
March 11

Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program

February 29Notice from the Executive Officer:Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act to update cost-sharing arrangements for non-low income seniors under the Ontario Drug Benefit (ODB) program
2015
DateTitle
November 23Notice from the Executive Officer: New Blood Glucose Test Strip Reimbursement Policy
November 13

Notice from the Executive Officer: Claims submission for prescriptions with drug costs over $10,000

October 13

Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2015-2016 Season and Claims Submission using the Health Network System

September 18Notice from the Executive Officer: Regulation Amendments to Streamline Submission Requirements for Certain Generic Products seeking Interchangeability Designations on the Ontario Drug Benefit Formulary
September 18Notice from the Executive Officer: Regulation Amendments to Support Sustainability and Access for the Ontario Public Drug Programs
September 18

Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program

July 23

Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act

May 20Notice from the Executive Officer: Tiered Generic Pricing Framework
March 10Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs

EO listing of terminated Health Network System Accounts

The following is a list of every pharmacy operation that has had its billing privileges revoked, its right to receive payment suspended, and its Health Network System (HNS) Subscription Agreement terminated, because the Executive Officer (EO) has reasonable grounds to believe that the operator has submitted unsupported and invalid claims for payment under the Ontario Drug Benefit (ODB) Program.

Pharmacy NameAddressCorporationOfficers/Directors/Shareholders
(OCP# if applicable)
Designated ManagerDate
3M Drug Mart7117 Bathurst Street
Unit 105 Thornhill, ON
St. Abu-Seifein Drugs Ltd.Maged (Mike) Hanna (215337)
Adel Tadros (111600)
Renee Samuel
Maged (Mike) Hanna (215337)April 7, 2020
ACE Pharmacy7-373 Steeles Avenue West
Brampton, ON
J B Kothari CorporationBhavesh Kothari (217389)Bhavesh Kothari (217389)August 31, 2012
Annex Optical Pharmacy882 Bathurst Street
Toronto, ON
747054 Ontario LimitedDavid (Michael) Wu (89818)David (Michael) Wu (89818)November 9, 2012
Akop’s Pharmacy14 Main Street
Elgin, ON
Akop’s Pharmacy Inc.Akop Shaboian (215101)Akop Shaboian (215101)April 11, 2017
Ayda Pharmacy1801 Eglinton Avenue West
Toronto, ON
Ayda Pharmacy Inc.Ragaie Khalil (205504)Ragaie Khalil (205504)March 24, 2014
Bathurst-Dundas Pharmacy Ltd. Guardian755-757 Dundas Street West
Toronto, ON
Bathurst-Dundas Pharmacy Ltd.Joy Abanzukwe (103497)Joy Abanzukwe (103497)September 2, 2008
Blossom Park Pharmacy2928 Bank Street
Ottawa, ON
Luke’s Pharmacy Inc.Luke Skywalker (72192)Luke Skywalker (72192)June 14, 2021
Central Weston Pharmacy & Medical Clinic2105 Weston Road
Toronto, ON
BBH Pharmacies & Medical Services Inc.Andrew Besada (610659)
Atef Besada (106836)
Andrew Besada (610659)July 17, 2019
Chapman’s Pharmacy648-650 Dundas Street
London, ON
2099065 Ontario Inc.Shamez Kassam (215893)
Kamaludin Kassam
Kinfe Blad (211876)May 30, 2019
Chesswood Pharmacy3750 Chesswood Drive, Unit 1
Toronto, ON
Chesswood Pharmacy Inc.Chi (Eric) Lo (116076)
Nestor Fernandez
Chi (Eric) Lo (116076)January 29, 2014
College Centre Pharmacy II528 College Street
Toronto, ON
St. Meena Pharmacy Ltd.Anhal Yacob (204896)Anhal Yacob (204896)March 26, 2021
Cundles Pharmacy18 Cundles Road East
Barrie, ON
Brown Wood Pharm. Inc.Daniel Hanna (210352)Daniel Hanna (210352)August 1, 2017
Danforth Medical Pharmacy1156 Danforth Avenue
Toronto, ON
Wellness Drug Mart Ltd.Magdy Salama (209088)Magdy Salama (209088)March 16, 2012
Dufferin Central Pharmacy1649 Dufferin Street
Toronto, ON
Dufferin Central Pharmacy Ltd.Leon Rawa (106747)
Michele Rawa
Leon Rawa (106747)December 21, 2020
Dukh Bhanjan Pharmacy475 Charolais Boulevard, Unit B5
Brampton, ON
2216001 Ontario Inc.Abhaya Dixit (214669)
Shady Mawad (218593)
Abhaya Dixit (214669)February 22, 2013
Elgin Mills Crossing I.D.A. Pharmacy3-10 John Birchall Road
Richmond Hill, ON
802246 Ontario LimitedNash Darani (79286)
Nargis Darani
Nash Darani (79286)September 22, 2016
Erie Health & Wellness Pharmacy101 Erie Street
Windsor, ON
8163219 Canada Ltd.Abdul Baqi (214965)
Nighat Nasreen
Tahira Naheed
Abdul Baqi (214965)November 4, 2014
Express Aid I.D.A. Pharmacy15 - 477 Grove Street
Barrie, ON
Express Aid Pharmacy on Grove Inc.Nimet Lalji (200976)
Sbhanji Holding Company
Nimet Lalji (200976)January 9, 2018
Finch Medical Pharmacy78 Finch Avenue East
Toronto, ON
Wellness Drug Mart Ltd.Magdy Salama (209088)Magdy Salama (209088)March 16, 2012
Guardian Drugs1995 Finch Avenue West
Toronto, ON
Pharmacia Drugs Ltd.Diep Ngoc Tran (101052)
Huucu Nguyen
Diep Ngoc Tran (101052)September 2, 2008
Health Link Pharmacy10555 Jane Street, Unit 8
Maple, ON
Health Link Consultants, IncFlora Farsad-Abarjy (215689)Flora Farsad-Abarjy (215689)August 10, 2012
Hi-Field Drug Mart792 Dundas Street West
Toronto, ON
Thi Pham BuuThi Phuong Khanh Pham Buu (103225)Thi Phuong Khanh Pham Buu (103225)October 22, 2009
IDA Hanin Drug Mart682 Bloor Street West
Toronto, ON
1188964 Ontario Inc.Magdy Salama (209088)
Amani Salama (216329)
Magdy Salama (209088)August 29, 2011
IDA Rideau Medical Pharmacy580 Rideau Street
Ottawa, ON
2281079 Ontario Inc.Waseem Shaheen (206544)Waseem Shaheen (206544)May 21, 2015
Island Plaza Pharmacy1A-540 King Street West
Oshawa, ON
2347032 Ontario Inc.Jerome Kan (609493)
Margaret Ting (201828)
Jerome Kan (609493)August 9, 2021
Jennas I.D.A. Pharmacy2-796 Burnhamthorpe Road West
Mississauga, ON
802246 Ontario LimitedNash Darani (79286) Nargis DaraniNash Darani (79286)September 22, 2016
Kim Pharmacy1198 Bloor Street West
Toronto, ON
1726878 Ontario Inc.Thi Kim Tien Nguyen (205136)Thi Kim Tien Nguyen (205136)November 2, 2009
Lawrence Medical Pharmacy1575 Lawrence Avenue West
Toronto, ON
Son Hing Drugs Inc.Sharon Son Hing
Lawrence Son Hing (65374)
Nicole Son Hing
Suzanne Son Hing
Elizabeth Toth (204196)
Elizabeth Toth (204196)April 13, 2012
Leone Pharmacy1615 Dufferin Street
Toronto, ON
2269669 Ontario LimitedLaureano Leone (20745)
Herman Ma (61492)
Herman Ma (61492)August 16, 2011
Lighthouse IDA Compounding Pharmacy130 Hollidge Boulevard
Aurora, ON
Lighthouse Inc.Jamil Rashid (205544)Jamil Rashid (205544)August 29, 2011
Lotus Pharmacy81 Huron Street
Toronto, ON
1554105 Ontario Ltd.Can Minh Le (201024)
Hai Le (110922)
Can Minh Le (201024)August 21, 2008
Main Drug Mart2558 Danforth Avenue
Toronto, ON
Mina Drug LimitedSouren Agemian (922)
Sherif Abdel Messih (67229)
Mervat Abdel Messih(67210)
Sherif Abdel Messih (67229)August 24, 2012
Main Drug Mart510 Trethewey Drive
Toronto, ON
A. & M. Drugs LimitedAtef Besada (106836)
Souren Agemian (922)
Atef Besada (106836)July 17, 2019
Medi-Pharm Pharmacy2535 Major Mackenzie Drive
Toronto
Peace Pharma IncZafar Ahmad (212220)
Naveed Ahmad (215069)
Ahsan Khan (203620)
Zafar Ahmad (212220)November 28, 2012
Metro Pharmacy500 Sheppard Avenue East
Toronto, ON
Triex International Inc.Shohreh Torabi (204608)
Hossein Ahmadian
Shohreh Torabi (204608)July 15, 2015
MT Cross Pharmacy503 Concession Street
Hamilton, ON
Concession Medical Clinic Inc.Ayman Mikhael (111279)
Amgad George Fahim
Safaa Eskander (116661)August 1, 2014
Mycurex Pharmacy Clinic40 Dundas Street West
Mississauga, ON
Sobhani Inc.Muhammad Subhani (82066)Muhammad Subhani (82066)September 2, 2014
MD Health Pharmacy186 Main Street South
Brampton, ON
St. Maharial Pharmacy Inc.Lilian Fam (608926)
Sameh Sadek (601938)
Sameh Sadek (601938)June 29, 2016
Neighbour’s Drug Mart330 Steeles Avenue West, Thornhill, ONNeighbour’s Drug Mart Ltd.Sina Salehi (614463; current director)

Galilna Pivovarov (91103; former director)
Sina Salehi (614463; current DM)

Galilna Pivovarov (91103; former DM)
September 16, 2022
Nhatrang Pharmacy673 College Street
Toronto, ON
Nhatrang Pharmacy Ltd.Ngu Van Hoa (101222)Ngu Van Hoa (101222)October 22, 2009
Noor Drug Mart3-640 Eglinton Avenue West
Mississauga, ON
Noor Drug Mart Inc.Eiman Amin (202872)
Galal Elsaigh
Eiman Amin (202872)August 21, 2013
Northcliffe Pharmacy1751 Eglinton Avenue West
Toronto, ON
Northcliffe Pharmacy LimitedSherif Gerges (205836)Sherif Samwaiel (218729)
Sandra Gerges (612561)
Sherif Samwaiel (218729)
Sylvia Mekhail (604292)
March 27, 2012
Oakwood Pharmacy332 Oakwood Avenue
Toronto, ON
St. Pola Drugs Inc.Maher Boazak (212036)Maher Boazak (212036)May 6, 2014
Olde Walkerville Pharmacy1701 Wyandotte Street East
Windsor, ON
Olde Walkerville Pharmacy Ltd.Bichoy Maurice (605094)
Mina Michael (218353)
Dejan Buric (621776)August 14, 2018
PARS Medical Pharmacy10171 Yonge Street
Richmond Hill, ON
Ultra Care Pharmacy Inc.Ahmed Hassan (610688)
Tamer Elokda (612346)
Tamer Mosallam (613562)August 20, 2015
Pharm Can Drug Mart71 Willow Street
Ottawa, ON
Pharm Can International Inc.Guo (Philip Sam)
Ma (213537)
Zou Pan
Guo (Philip Sam)
Ma (213537)
November 23, 2017
Pharm Can Drug Mart71 Willow Street
Ottawa, ON
Hanhan Inc.Bingyi Han (620381)Bingyi Han (620381)October 7, 2022
Pharmalinx Guardian Pharmacy2101 Brimley Road, Unit 103
Toronto, ON
Pharmalinx Medical Centre Inc.Shani-Abbas (Shani) Siwani (614754)
Juma Sarfraz
Murtaza Jacksi
Shani-Abbas (Shani) Siwani (614754)November 14, 2019
Rathburn Pharmacy592 Rathburn Road West
Mississauga, ON
St. Philopateer Drugs Inc.Said Attalla (209632)Said Attalla (209632)July 21, 2011
Remedy's Rx Brock Medical Pharmacy1637 Dundas Street West
Toronto, ON
2037424 Ontario Inc.Joy Abanzukwe (103497)Stanislava (Stanya)
Louda (209276)
August 14, 2018
Rexdale Mall Pharmacy6-2267 Islington Avenue
Toronto, ON
9095357 Canada Ltd.Abdul Wajid (215313)
Muhammad Ashraf (206788)
Rehana Yasmeen Khan
Abdul Wajid
(215313)
July 13, 2022
Rideau Pharmacy390 Rideau Street
Ottawa, ON
1900008 Ontario Inc.Amir Kamel (613681)
John Phlamon (605411)
Pierre Nasralla (208584)
Amir Kamel (613681)
Mirelle (Mira) Tawdrous
(618681)
Ashraf Luca (621651)
August 14, 2018
Rose Pharmacy2077 Weston Road
Toronto, ON
Dong Phuong Hong Drugs Ltd.Hong Khac Ngo (106283)Hong Khac Ngo (106283)June 13, 2008
Richmond Medical Pharmacy9206 Yonge Street
Richmond Hill, ON
1573548 Ontario Inc.Joseph Salek (77224)Atossa Babaie-Nami (212753)August 16, 2011
Sheppard Warden Pharmacy3410 Sheppard Avenue East
Toronto, ON
St. Cyril Drugs Ltd.Nashaat Ramzy (106801)Nashaat Ramzy (106801)December 7, 2011
Spadina Avenue Pharmacy300B Spadina Avenue
Toronto, ON
Spadina Avenue Pharmacy Ltd.Olusola Alugo (211872)
Tien Nguyen
Olusola Alugo (211872)July 25, 2008
St. Laurent IDA Pharmacy1237 Donald Street
Gloucester, ON
Three Angels Pharma Inc.Maged Ghoubrial (612453)
Amir Sedrak (621781)
Amir Sedrak (621781)November 3, 2021
Sunshine Pharmacy1183 Weston Road
Toronto, ON
Maranatha Pharmacy Group Inc.Sami Naguib (212412)Ovietobore (Felix) Ayigbe (204476)
Ovietobore (Felix) Ayigbe (204476)
August 26, 2011
Supercare Pharmacy2867 Jane Street
Downsview, ON
Maranatha Drugs Inc.Said Attalla (209632)
Gina Ghobrial (212885)
Gina Ghobrial (212885)July 13, 2012
Swiderski Pharmacy1-3015 Parkerhill Road
Mississauga, ON
Swiderski Pharmacy Ltd.Richard Swiderski (112321)
Joanna Swiderski (202372)
Richard Swiderski (112321)August 18, 2017
Tamimi Pharmacy1760 Tecumseh Road
Windsor, ON
Tamimi Pharmacy Ltd.Khalid Al-Tamimi (612849)
Ahmed Al-Tamimi (215793)
Ahmed Al-Tamimi (215793)January 9, 2012
Torbram Pharmacy1090 Peter Robertson Boulevard
Brampton, ON
2023059 Ontario Inc.Sangita Sharma (112437)
Abhay Sharma
Rita Jurkuvenas (52086)January 18, 2018
Total Care Pharmacy3155 Eglinton Avenue East
Scarborough, ON
Mona Yacoub Drug LimitedMona Yacoub (210496)Nancy Wu (51632)February 15, 2012
Total Health #110799 Bloor Street West
Toronto, ON
JSMMA Inc.Sherif Gerges (205836)
Sandra Gerges (612561)
Sherif Samwaiel (218729)
Sylvia Mekhail (604292)
Sherif Samwaiel (218729)August 26, 2011
Total Health #1193251 Sheppard Avenue East
Scarborough, ON
Natsherri Inc.Sherif Gerges (205836)
Masoud Amidi-Mazaheri (609114)
Sherif Samwaiel (218729)
Hany Kot (216513)
Sherif Samwaiel (218729)August 26, 2011
Vanguard Drug Mart565 College Street
Toronto, ON
Van-To Pharmacy LimitedTo Ha (88919)To Ha (88919)August 16, 2011
Vaughan Neighbourhood Pharmacy68-3175 Rutherford Road
Vaughan, ON
1695781 Ontario CorporationThi (Tammy) Minh Thu Mai (213249)
Khanh Cong Bui
Thi (Tammy) Minh Thu Mai (213249)August 18, 2008
Warden Pharmacy119-30 Gibson Drive
Markham, ON
AS169988 Consultants Inc.Xiao Ning (Sean) Xu (609448) Wu Ying PengXiao Ning (Sean) Xu
(609448)
September 25, 2017
Wellmart Pharmacy347 Spadina Avenue
Toronto, ON
1466409 Ontario Inc.Can Minh Le (201024)Can Minh Le (201024)August 21, 2008
West End Medical Pharmacy2209 Bloor Street West
Toronto, ON
St. Barbara's Pharmacy LtdOmelan Chabursky (6068)Natalya Ivasiv (220077)August 26, 2014
Westview Pharmacy2115 Finch Avenue West
Toronto, ON
A and 2M Drugs LimitedAmany Hanna (214829)
Ihab Yacoub (214493)
Amir Besada (96326)
Amany Hanna (214829)March 24, 2010
Wilson Medical Pharmacy554 Main Street East
Hamilton, ON
Safaa Pharmacy Inc.Souren Agemian (922) Safaa Eskander (116661) Ayman Mikhael (111279)Safaa Eskander (116661)February 22, 2012

The following is a list of every pharmacy operator that has received notice from the EO of Ontario Public Drug Programs that it may have its billing privileges revoked, its right to receive payment suspended, and its HNS Subscription Agreement terminated, because the EO has reasonable grounds to believe that the operator has submitted unsupported and invalid claims for payment under the Ontario Public Drug Programs.

Pharmacy NameAddressCorporationOfficers/Directors/Shareholders
(OCP# if applicable)
Designated ManagerDate
N/AN/AN/AN/AN/AN/A

Archived Executive Officer Communications

Historical archive of individual Executive Officer Communications published prior 2015